| Powder: | Yes |
|---|---|
| Customized: | Customized |
| Certification: | GMP, HSE, ISO 9001, USP, BP, SGS |
| Suitable for: | Adult |
| State: | Powder |
| Purity: | 99% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
| Product Name | Sonwu Supply Ponatinib Powder Ponatinib Intermediate Ponatinib |
| CAS NO. | 943319-70-8 |
| MF | C29H27F3N6O |
| MW | 532.56 |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Appearance | White Powder |
| Certificate | ISO, SGS, GMP, HACCP |
| Assay Method | HPLC |
| Extraction Type | Solvent Extraction |
| Sample | Available |
| MOQ | 5g |
| Shelf life | 2 Years |
| Storage | Store in cool & dry place not freeze Keep away from strong light and heat |
1. Panatinib successfully suppressed the function of the BCR-ABL mutation in patients with refractory chronic myelogenous leukemia in a phase I clinical trial. The significance of the changes in both the incidence and FLT-ITD suggests that this enzyme plays an important role in tumor regression.
2. Panatinib not only inhibits BCR-ABL itself and its mutants at an effective concentration in clinical practice, but also inhibits FLT3 Kit in vitroFiber cell growth factor receptor 1 (FGFR1) and platelet-derived growth factor receptor alpha (PDGFR alpha) activity, with containing these receptors active forms of leukemia cell line experiment, we find that it can effectively inhibit receptor phosphorylation and cell proliferation, in patients with acute myeloid leukemia, for he are activated to restrain activity of FLT3 - ITD mutants of 30%, in MV4-11 (FLT3 ITD + / +) in acute myeloid leukemia cells, the, for, in less than 10 nmol/L concentrations can inhibit FLT3 signal and the induction of apoptosis.
3. Ponatinib inhibited all of the BCR-ABL mutant strains in the assay, and BCR-ABT315I inhibited tumor cells in mice. Panatinib is a broad-spectrum active BCR-ABL inhibitor for the treatment of chronic myelogenous leukemia.For, inhibition of cell growth, expression of BCR - ABL itself or its variant, will, for his role of mononuclear cells from leukemia patients after fine Chemicalbook cell number 500 times less than the normal, he for he also inhibit BCR - ABLT315I kinase activity and primary chronic myelogenous leukemia cell colony formation, SRC, FGFR, VEGFR and PDGFR kinase family is all sorts of potential targets of malignancy,, for can inhibit these kinases, is a broad drug for the treatment of tumor.
4. Ponatinib is an anticancer drug. It was approved by FDA in December 2012 for the treatment of adult chronic myelogenous leukemia (CML) and "Philadelphia chromosome positive" (PH +) acute lymphoblastic leukemia (ALL). It is mainly used to treat patients who do not respond to dasatinib or nillotinib therapy, or who are unable to tolerate dasatinib or nillotinib, and who are not suitable for subsequent treatment with imatinib. It can also be used to treat patients with a genetic mutation (the "T315I mutation") that makes patients resistant to imatinib, dasatinib, or nilotinib. It is also used to treat CML and pH +ALL in adults who have not been treated with other TKIs. It is currently the only marketed drug that is effective against the BCR-ABL kinase T315I mutation.
5. Ponatinib was approved in the European Union in July 2013 through a centralised approval process. Panatinib is the third generation of multi-target tyrosine kinase inhibitors. Typical drugs of multi-target tyrosine kinase inhibitors include sunitinib, imatinib, sorafenib and vataranib., for he (Ponatinib) can effectively inhibit the in vitro FGFR1-4 kinase activity, its IC50 alue concentration,2,18 2 and 8 nmol/L respectively, in the absence of interleukin - 3 cells, FGFR1, on behalf of, to curb cells - 4 kinase expression of IC50 alue concentration were 8 August 24 and 34 nmol/L, and tested in each cell, for inhibition of FGFR1-4 phosphorylation, its IC50 alue concentration is 39 29 32 and 39 nmol/L respectively tested on endometrial bladder Stomach and thymus in multiple cell lines FGFR inhibition, relatively, compared with other drugs for showed obvious pharmacological effects, such as its inhibit endometrial AN3CA and MFE - 296 cell proliferation GI50 value of 14 and 61 nmol/L, it shows that, for he is a powerful FGFR inhibitors in mice tumor xenograft model, each day 10 mg/kg or 30 mg/kg, tumor inhibition rate were 49% and 82%, respectively.
| Other Hot-Selling Similar Products | ||||
| Capecitabine | Everolimus | Afatinib | Vandetanib | Gefitinib |
| Temozolomid | Rapamycin | Axitinib | Sorafenib tosylate | Cediranib |
| Cabozantinib | Selumetinib | Crizotinib | Sunitinib malate | Erlotinib |
| Crizotinib | Lapatinib | Debrafenib | Cabazitaxel | Ponatinib |
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}